Prot #HCCBAYLOR12: A 36-Month Multi-Center, Open Label, Randomized, Comparator Study to Evaluate the Efficacy and Safety of Everolimus Immunosuppression Treatment in Liver Transplantation for Hepatocellular Carcinoma Exceeding Milan Criteria

Project: Research project

Project Details

StatusFinished
Effective start/end date8/11/143/31/22

Funding

  • Baylor Research Institute (Prot #HCCBAYLOR12 // Prot #HCCBAYLOR12)
  • Novartis Pharmaceuticals Corporation (Prot #HCCBAYLOR12 // Prot #HCCBAYLOR12)